Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 29c; offers guidance
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $237.51 -1.44%
EPS Growth %: +174.9%
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
CRMT, FOMI, FLES, More
EPS Growth %: +174.9%
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
CRMT, FOMI, FLES, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $3.95, $0.29 worse than the analyst estimate of $4.24. Revenue for the quarter came in at $892.8 million versus the consensus estimate of $896.9 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2023 EPS of $16.90-$17.85, versus the consensus of $17.44. Jazz Pharmaceuticals sees FY2023 revenue of $3.675-3.875 billion, versus the consensus of $3.78 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
- Innovex closes $95M acquisition of TCO Group AS
- NHC acquires 35 facilities from NHI for $560 million
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
